AI assistant
IMPEDIMED LIMITED — Capital/Financing Update 2010
Nov 15, 2010
65135_rns_2010-11-15_58e32ef3-6b37-4805-ae3f-551bc70b29b5.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [110 x 105] intentionally omitted <==
----- Start of picture text -----
ASX: IPD
----- End of picture text -----
16 November 2010
ASX RELEASE
Listing Rule 6.22 - Options
ImpediMed Limited (the Group) today announced that effective 8 April 2010 in accordance with Listing Rule 6.22, the exercise price for the Quoted Options (IPDO) was reduced from $0.7079 per IPDO to $0.7012 per IPDO. The exercise price for each of the unquoted options outstanding as of 8 April 2010 was reduced by approximately $0.01 as detailed in the below table.
Announced on 11 February 2010
ImpediMed Limited announced that effective 2 July 2009 in accordance with Listing Rule 6.22, the exercise price for the Quoted Options (IPDO) was reduced from $0.72 per IPDO to $0.7079 per IPDO.
The exercise price for each of the unquoted options outstanding on 2 July 2009 was reduced by approximately $0.01 as detailed in the below table.
The unquoted options were issued at various dates with various exercise prices and expiration dates. The effects of these reductions on the outstanding unquoted options are summarized in the table below.
| ASX ref | Original Exercise Price |
Original Exercise Price |
2 July 2009 Revised Exercise Price |
2 July 2009 Revised Exercise Price |
8 April 2010 Revised Exercise Price |
8 April 2010 Revised Exercise Price |
Currently Outstanding |
Expiration |
|---|---|---|---|---|---|---|---|---|
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
50,001 | 30-Jul-10 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
50,001 | 30-Jul-11 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
49,998 | 29-Jul-12 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
50,000 | 28-Oct-10 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
50,000 | 28-Oct-11 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
50,000 | 28-Oct-12 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
83,333 | 23-Nov-10 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
83,333 | 23-Nov-11 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
83,334 | 23-Nov-12 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
26,667 | 24-Dec-10 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
26,667 | 24-Dec-11 |
| IPDAO | $ | 0.8700 |
$ | 0.8579 |
$ | 0.8512 |
26,666 | 24-Dec-12 |
| IPDAO | $ | 1.0300 |
$ | 1.0179 |
$ | 1.0112 |
166,667 | 31-Jul-12 |
| IPDAO | $ | 1.0300 |
$ | 1.0179 |
$ | 1.0112 |
166,667 | 31-Jul-13 |
| IPDAO | $ | 1.0300 |
$ | 1.0179 |
$ | 1.0112 |
166,666 | 31-Jul-14 |
Page 1 of 2
| ASX ref | Original Exercise Price |
Original Exercise Price |
2 July 2009 Revised Exercise Price |
2 July 2009 Revised Exercise Price |
8 April 2010 Revised Exercise Price |
8 April 2010 Revised Exercise Price |
Outstanding | Expiration |
|---|---|---|---|---|---|---|---|---|
| IPDAQ | $ | 0.6750 |
$ | 0.6629 |
$ | 0.6562 |
249,225 | 31-Dec-11 |
| IPDAQ | $ | 0.6750 |
$ | 0.6629 |
$ | 0.6562 |
249,224 | 31-Dec-12 |
| IPDAQ | $ | 0.6750 |
$ | 0.6629 |
$ | 0.6562 |
249,224 | 31-Dec-13 |
| IPDAO | $ | 0.7160 |
$ | 0.7039 |
$ | 0.6972 |
175,000 | 29-May-12 |
| IPDAO | $ | 0.7160 |
$ | 0.7039 |
$ | 0.6972 |
175,000 | 29-May-13 |
| IPDAO | $ | 0.7160 |
$ | 0.7039 |
$ | 0.6972 |
175,000 | 29-May-14 |
| IPDAM | $ | 0.9100 |
$ | 0.8979 |
$ | 0.8912 |
166,667 | 31-Jul-12 |
| IPDAM | $ | 0.9100 |
$ | 0.8979 |
$ | 0.8912 |
166,667 | 31-Jul-13 |
| IPDAM | $ | 0.9100 |
$ | 0.8979 |
$ | 0.8912 |
166,666 | 31-Jul-14 |
| IPDAU | $ | 0.7347 |
$ | 0.7226 |
$ | 0.7159 |
392,666 | 31-Dec-13 |
| IPDAU | $ | 0.7347 |
$ | 0.7226 |
$ | 0.7159 |
392,666 | 31-Dec-14 |
| IPDAU | $ | 0.7347 |
$ | 0.7226 |
$ | 0.7159 |
392,665 | 31-Dec-15 |
| IPDAI | $ | 0.7022 |
$ | 0.6901 |
$ | 0.6834 |
140,000 | 31-Dec-14 |
| IPDAI | $ | 0.7022 |
$ | 0.6901 |
$ | 0.6834 |
140,000 | 31-Dec-15 |
| IPDAI | $ | 0.7022 |
$ | 0.6901 |
$ | 0.6834 |
140,000 | 31-Dec-16 |
| IPDAK | $ | 0.7865 |
(A) | $ | 0.7798 |
678,504 | 31-Dec-14 | |
| IPDAK | $ | 0.7865 |
(A) | $ | 0.7798 |
678,503 | 31-Dec-15 | |
| IPDAK | $ | 0.7865 |
(A) | $ | 0.7798 |
678,503 | 31-Dec-16 |
(A) - Not on issue as of 2 July 2009.
Stephen Denaro Company Secretary
ENDS For further information contact:
Greg Brown ImpediMed CEO T: 61-7-3860-3700 Mobile/Cell: +61408281127
About ImpediMed
ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.
For more information, visit. www.impedimed.com.
Page 2 of 2